Quest Diagnostics Incorporated $DGX Shares Sold by ABN Amro Investment Solutions

ABN Amro Investment Solutions trimmed its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 16.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 80,781 shares of the medical research company’s stock after selling 15,567 shares during the quarter. ABN Amro Investment Solutions owned approximately 0.07% of Quest Diagnostics worth $15,395,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC acquired a new position in Quest Diagnostics in the fourth quarter worth about $323,000. Concurrent Investment Advisors LLC grew its position in shares of Quest Diagnostics by 6.1% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 2,218 shares of the medical research company’s stock worth $398,000 after acquiring an additional 128 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Quest Diagnostics by 14.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 10,478 shares of the medical research company’s stock worth $1,879,000 after acquiring an additional 1,362 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of Quest Diagnostics by 18.0% in the 2nd quarter. TD Asset Management Inc now owns 121,014 shares of the medical research company’s stock valued at $21,738,000 after acquiring an additional 18,484 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Quest Diagnostics during the 2nd quarter valued at approximately $242,000. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $206.66 on Friday. Quest Diagnostics Incorporated has a 12-month low of $157.20 and a 12-month high of $213.20. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market capitalization of $22.99 billion, a price-to-earnings ratio of 23.62, a price-to-earnings-growth ratio of 2.67 and a beta of 0.66. The business has a 50 day simple moving average of $183.25 and a 200 day simple moving average of $182.51.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.35 by $0.07. Quest Diagnostics had a return on equity of 15.57% and a net margin of 8.99%.The company had revenue of $2.81 billion during the quarter, compared to analyst estimates of $2.75 billion. During the same quarter in the previous year, the firm posted $2.23 EPS. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics declared that its board has initiated a share repurchase program on Tuesday, February 10th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 4.7% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 20th. Investors of record on Monday, April 6th will be given a $0.86 dividend. The ex-dividend date is Monday, April 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.7%. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s payout ratio is currently 36.57%.

Key Stories Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Better-than-expected Q4 results and 2026 guidance: Q4 EPS $2.42 vs. $2.35 est., revenue $2.81B vs. $2.75B est., and FY‑2026 EPS guidance of $9.45–$9.65 — supports the recent run to a 12‑month high. Quest Diagnostics Hits New 12-Month High on Better-Than-Expected Earnings
• Positive Sentiment: $1.0 billion share repurchase authorization (~4.7% of shares outstanding): board buyback typically supports EPS and signals management thinks shares are undervalued. Quest Diagnostics Board Approves Stock Repurchase Program
• Positive Sentiment: Dividend increase: quarterly dividend raised to $0.86 (annualized $3.44), up from $0.80 — incremental income support and a sign of confidence in cash flow. Quest Diagnostics Has Announced That It Will Be Increasing Its Dividend To $0.86
• Positive Sentiment: Analyst bullishness: Mizuho upgraded to Buy and raised its target to $235 (largest recent target raise), and Citigroup published a constructive price‑appreciation forecast — these lifts can attract demand and support the stock. Quest Diagnostics Gets a Buy from Mizuho Securities Citigroup Forecasts Strong Price Appreciation for Quest Diagnostics
• Neutral Sentiment: Valuation/mean‑reversion questions: coverage pieces note DGX is at a 52‑week high and review whether recent strength is sustainable — useful for gauging risk/reward but not new fundamental data. Can the Run Continue?
• Negative Sentiment: Insider selling: SVP Patrick Plewman sold 5,662 shares (~27% of his holding) at about $204 — insider sales can be viewed negatively by some investors even when proceeds are routine. SVP Patrick Plewman Sells 5,662 Shares

Insider Activity at Quest Diagnostics

In related news, Director Vicky B. Gregg sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $191.76, for a total transaction of $239,700.00. Following the sale, the director owned 17,037 shares of the company’s stock, valued at $3,267,015.12. The trade was a 6.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mark E. Delaney sold 7,946 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $187.35, for a total value of $1,488,683.10. Following the completion of the sale, the senior vice president owned 7,530 shares of the company’s stock, valued at $1,410,745.50. This trade represents a 51.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 69,951 shares of company stock worth $13,473,408 in the last 90 days. Corporate insiders own 8.16% of the company’s stock.

Wall Street Analysts Forecast Growth

DGX has been the subject of a number of research reports. Leerink Partners lifted their price objective on shares of Quest Diagnostics from $203.00 to $210.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Evercore ISI set a $220.00 target price on shares of Quest Diagnostics in a report on Wednesday. Piper Sandler lifted their target price on Quest Diagnostics from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Robert W. Baird set a $219.00 price target on Quest Diagnostics in a research report on Wednesday. Finally, Citigroup raised their price target on Quest Diagnostics from $190.00 to $215.00 and gave the stock a “neutral” rating in a report on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $208.93.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.